Zolpidem Induced Depersonalization and Derealization
Publish place: World Conference on Psychology and Educational Sciences, Law and Social Sciences at the Beginning of the Third Millennium
Publish Year: 1395
نوع سند: مقاله کنفرانسی
زبان: English
View: 410
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
PESLS01_376
تاریخ نمایه سازی:
Abstract:
Zolpidem is an imidazopyridine agent indicated for the short-term treatment of insomnia (1, 2). Due to its milder and lower problematic side effects, chemically distinction from benzodiazepines and apparent selectively binding to a subset of benzodiazepine receptors, it has gained popularity as an alternative to benzodiazepine for the treatment of insomnia (3). This property may account for their apparently milder withdrawal effects. Zolpidem exerts hypnotic effect comparable to short- and medium-acting benzodiazepines, and shown similar or possibly fewer adverse reactions at the therapeutic doses (2), except for gastrointestinal disturbances which appear to be more common as well as visual hallucinations especially in women. On the other hand, zolpidem unexpectedly causes as much memory impairment as triazolam does, if not more, at least in young healthy adults (4).Depersonalization (DP), a complex and obscure subject of clinical psychiatry, has become a recurrent topic of psychopathology in the last 10 years (5). It is characterized by persistent or recurrent episodes of the patient detachment from him/herself. It means that individuals may feel like an automaton or they may have a sensation of estrangement from their own mental processes, emotions or body shape (5-8). Often accompanied by derealization (DR), a threatening sense of unreality from the environment, DP can assume various nuanced forms in clinical practice (5, 9-15).The purpose of this case report is to review the diagnosis of depersonalization/derealization disorder (DDD) Zolpidem use. Numerous case reports of DDD and articles about zolpidem s potential neuropsychiatric symptoms have been published. However, and to our knowledge, this is the first case report describing the onset of DDD following zolpidem exposure.
Authors
Mohammad Reza Aedini
Cellular and molecular research center, Associate professor of pharmacology, Birjand University of Medical Science, Birjand, Iran
Ali Akbar Esmaeili
Psychiatry and behavioral sciences research center, Assistant professor of psychiatry, Birjand University of Medical Science, Birjand, Iran
Mahboubeh Saljoughi
Ms.c Clinical Psychology, Hepatitis Research Center, Birjand University of Medical Sciences, Birjand, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :